Table of Contents Author Guidelines Submit a Manuscript
Research Article
Mediators of Inflammation
Volume 2015, Article ID 871641, 3 pages
http://dx.doi.org/10.1155/2015/871641
Letter to the Editor

Comment on “5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity”

National Veterinary Institute, Technical University of Denmark, 1870 Frederiksberg, Denmark

Received 13 January 2015; Accepted 21 January 2015

Academic Editor: Jagadeesh Bayry

Copyright © 2015 Thomas Mørch Frøsig and Sine Reker Hadrup. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Stübig, A. Badbaran, T. Luetkens et al., “5-Azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity,” Mediators of Inflammation, vol. 2014, Article ID 418292, 12 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. A. O. Gang, T. M. Frøsig, M. K. Brimnes et al., “5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies,” Blood Cancer Journal, vol. 4, no. 3, article e197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. L. R. Silverman, E. P. Demakos, B. L. Peterson et al., “Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2429–2440, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Qiu, C. Hother, U. M. Ralfkiaer et al., “Equitoxic doses of 5-Azacytidine and 5-Aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome,” PLoS ONE, vol. 5, no. 9, Article ID e12994, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Dubovsky, D. G. McNeel, J. J. Powers, J. Gordon, E. M. Sotomayor, and J. A. Pinilla-Ibarz, “Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen,” Clinical Cancer Research, vol. 15, no. 10, pp. 3406–3415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Goodyear, A. Agathanggelou, I. Novitzky-Basso et al., “Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia,” Blood, vol. 116, no. 11, pp. 1908–1918, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Coral, L. Sigalotti, A. Gasparollo et al., “Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR),” Journal of Immunotherapy, vol. 22, no. 1, pp. 16–24, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Moon, S. H. Kim, K. S. Park et al., “Use of epigenetic modification to induce FOXP3 expression in Naïve T cells,” Transplantation Proceedings, vol. 41, no. 5, pp. 1848–1854, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. O. C. Goodyear, M. Dennis, N. Y. Jilani et al., “Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML),” Blood, vol. 119, no. 14, pp. 3361–3369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Marcucci, L. Silverman, M. Eller, L. Lintz, and C. L. Beach, “Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes,” Journal of Clinical Pharmacology, vol. 45, no. 5, pp. 597–602, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. X.-N. Gao, J. Lin, L.-L. Wang, and L. Yu, “Demethylating treatment suppresses natural killer cell cytolytic activity,” Molecular Immunology, vol. 46, no. 10, pp. 2064–2070, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. B. J. Schmiedel, V. Arélin, F. Gruenebach, M. Krusch, S. M. Schmidt, and H. R. Salih, “Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation,” International Journal of Cancer, vol. 128, no. 12, pp. 2911–2922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. M. Williams and R. E. Gress, “Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation,” Best Practice and Research: Clinical Haematology, vol. 21, no. 3, pp. 579–596, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Vanneman and G. Dranoff, “Combining immunotherapy and targeted therapies in cancer treatment,” Nature Reviews Cancer, vol. 12, no. 4, pp. 237–251, 2012. View at Publisher · View at Google Scholar · View at Scopus